title: Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors.
authors.forename: A
authors.initials: A
authors.lastname: Calcagno
authors.forename: M C
authors.initials: MC
authors.lastname: Tettoni
authors.forename: M
authors.initials: M
authors.lastname: Simiele
authors.forename: L
authors.initials: L
authors.lastname: Trentini
authors.forename: C
authors.initials: C
authors.lastname: Montrucchio
authors.forename: A
authors.initials: A
authors.lastname: D'Avolio
authors.forename: G
authors.initials: G
authors.lastname: Di Perri
authors.forename: S
authors.initials: S
authors.lastname: Bonora
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000069446:Atazanavir Sulfate; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage*; D010949:Plasma / Q000737:chemistry; D011725:Pyridines / Q000008:administration & dosage*; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000068898:Raltegravir Potassium; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage*
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D011760:Pyrrolidinones; D018894:Reverse Transcriptase Inhibitors; D000068898:Raltegravir Potassium; D000069446:Atazanavir Sulfate; D019438:Ritonavir